乳腺MRI预测新辅助化疗反应在有或无钼靶钙化患者中等效
该回顾性研究纳入114例接受新辅助化疗的乳腺癌患者,比较有或无钼靶钙化两组中MRI预测化疗反应与术后病理的一致性。结果显示两组pCR率相似(37% vs 38%),MRI预测与病理的相关性均为69%(p=0.988),表明MRI预测不依赖于钙化存在与否,建议根据新辅助化疗后MRI而非钼靶制定手术方案。
要点
- MRI预测新辅助化疗反应在有或无钼靶钙化患者中一致性均为69%,无显著差异。
- 残余钼靶钙化不能充分预测残余浸润性疾病,应依据MRI评估反应。
- ER阴性/HER2阳性肿瘤更常见钙化,三阴性肿瘤罕见钙化。
英文原文(摘要)· 点击展开
OBJECTIVES: Current surgical policy recommends comprehensive excision of tumorous calcifications in breast cancer patients following neoadjuvant chemotherapy (NAC) regardless of MRI outcomes, despite MRI defining tumor response superior to mammography. The current study examines MRI prediction of response in tumors with vs without calcifications, using post-NAC surgical pathology as the standard of reference.
METHODS: Retrospective analysis of 114 NAC patients between 2011 and 2018 including demographics, mammography, 3 T-MRI, and pathology compared two sub-groups: without (n = 62) or with (n = 52) mammographic calcifications. In the calcification cohort, the mammographic extent of calcifications and MRI enhancement overlapped. MRI prediction of response to NAC was correlated with pathology. Two-tailed paired T and Fisher's exact tests and Cohen's kappa coefficient were applied for analysis.
RESULTS: There was no significant difference between the two sub-groups regarding demographics. Tumors demonstrated equivalent features regarding size, lymph node involvement, and DCIS component. ER-negative/HER2-positive tumors more commonly exhibited calcifications (33% n = 17 calcified vs 13% n = 8 non-calcified; p < 0.05); triple negative pathology rarely calcified (6% n = 3 calcified vs 33% n = 20 non-calcified; p < 0.05). NME was more common with calcifications (62% n = 32 calcified vs 29% n = 18 non-calcified; p < 0.05) and mass enhancement without (90% n = 56 non-calcified vs 81% n = 42 calcified; p < 0.05). Both groups responded similarly to NAC (pCR = 37% non-calcified vs 38% calcified); response on MRI equally correlated with pathology (69% both subgroups; p = 0.988).
CONCLUSION: We propose utilizing post-NAC MRI findings rather than mammography in planning surgery, as MRI prediction is independent of the presence or absence of calcifications. Prospective studies to evaluate this approach are warranted.
KEY POINTS: • No difference was found in demographic, clinical, pathology, or imaging characteristics between patients with or without tumoral calcifications on mammography prior to neoadjuvant chemotherapy. • Residual mammographic calcifications are inadequate predictors of residual invasive disease. MRI accurately recognized complete response and correctly correlated with post-treatment surgical pathology in 69% of patients, regardless of the presence or absence of mammographic calcifications. • We propose utilizing post-NAC MRI findings rather than mammography in planning post-NAC surgery, as MRI prediction of response is independent of the presence or absence of calcifications.
引用
- Sella, Simor, Adler-Levy, et al. MRI prediction of neoadjuvant chemotherapy response is equivalent in patients with or without mammographic calcifications: a step towards adapting surgical approach? Eur Radiol. 2023. PMID: 37086288. doi:10.1007/s00330-023-09640-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。